What is HC Wainwright’s Forecast for ARWR FY2025 Earnings?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – HC Wainwright dropped their FY2025 earnings per share (EPS) estimates for shares of Arrowhead Pharmaceuticals in a research report issued to clients and investors on Monday, September 15th. HC Wainwright analyst P. Trucchio now anticipates that the biotechnology company will post earnings of ($0.23) per share for the year, down from their previous forecast of ($0.20). HC Wainwright currently has a “Buy” rating and a $80.00 target price on the stock. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Arrowhead Pharmaceuticals’ Q4 2025 earnings at ($0.38) EPS, Q1 2026 earnings at $1.83 EPS, Q2 2026 earnings at ($1.01) EPS, Q3 2026 earnings at ($1.23) EPS, Q4 2026 earnings at ($1.23) EPS, FY2026 earnings at ($1.66) EPS, FY2027 earnings at ($3.19) EPS, FY2028 earnings at ($3.36) EPS and FY2029 earnings at ($1.61) EPS.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share for the quarter, missing the consensus estimate of ($0.94) by ($0.32). The firm had revenue of $27.77 million during the quarter, compared to analyst estimates of $29.01 million. During the same quarter in the prior year, the company earned ($1.38) earnings per share.

Several other equities research analysts also recently commented on ARWR. B. Riley upgraded Arrowhead Pharmaceuticals to a “strong-buy” rating in a report on Monday, August 11th. Chardan Capital reiterated a “buy” rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a report on Monday, August 11th. TD Cowen upgraded Arrowhead Pharmaceuticals to a “strong-buy” rating in a report on Monday, July 28th. Wall Street Zen downgraded Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, July 18th. Finally, Royal Bank Of Canada dropped their target price on Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an “outperform” rating on the stock in a report on Friday, August 8th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $43.14.

Arrowhead Pharmaceuticals Stock Performance

NASDAQ ARWR opened at $29.13 on Wednesday. The firm has a market capitalization of $4.03 billion, a P/E ratio of -22.76 and a beta of 1.00. The company has a debt-to-equity ratio of 0.39, a current ratio of 4.87 and a quick ratio of 4.87. Arrowhead Pharmaceuticals has a 1-year low of $9.57 and a 1-year high of $31.13. The business’s 50-day simple moving average is $20.67 and its 200-day simple moving average is $16.76.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. grew its position in shares of Arrowhead Pharmaceuticals by 8.4% in the 1st quarter. Vanguard Group Inc. now owns 13,202,562 shares of the biotechnology company’s stock worth $168,201,000 after acquiring an additional 1,018,273 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Arrowhead Pharmaceuticals by 138.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,785,062 shares of the biotechnology company’s stock worth $60,962,000 after acquiring an additional 2,774,933 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Arrowhead Pharmaceuticals by 1.0% in the 2nd quarter. Geode Capital Management LLC now owns 2,978,505 shares of the biotechnology company’s stock worth $47,067,000 after acquiring an additional 28,193 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its position in shares of Arrowhead Pharmaceuticals by 0.9% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 2,528,982 shares of the biotechnology company’s stock worth $32,220,000 after acquiring an additional 21,686 shares in the last quarter. Finally, Marshall Wace LLP boosted its position in Arrowhead Pharmaceuticals by 3,507.8% during the 2nd quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company’s stock valued at $34,065,000 after purchasing an additional 2,096,238 shares during the period. Institutional investors and hedge funds own 62.61% of the company’s stock.

Insider Activity at Arrowhead Pharmaceuticals

In other news, insider James C. Hamilton sold 15,000 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $30.00, for a total value of $450,000.00. Following the completion of the transaction, the insider owned 232,122 shares in the company, valued at approximately $6,963,660. This trade represents a 6.07% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last ninety days, insiders sold 40,000 shares of company stock valued at $1,025,000. 4.30% of the stock is currently owned by company insiders.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.